- Investors :: Codexis, Inc. (CDXS)
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes
- Codexis Introduces Improved Enzymes to Further Enhance Tate Lyles . . .
REDWOOD CITY, Calif and HOFFMANN ESTATES, Ill , Jan 13, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Tate Lyle (LSE: TATE L), a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the
- Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key . . .
REDWOOD CITY, Calif , Dec 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR)
- Codexis Reports First Quarter 2021 Financial Results
REDWOOD CITY, Calif , May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter ended March 31, 2021 and provided a business update
- Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical . . .
REDWOOD CITY, Calif , Feb 06, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co , Ltd for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an active ingredient in Beova ® Tablets, a novel, once-daily treatment for overactive
- News Events - Codexis, Inc.
REDWOOD CITY, Calif , June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc , a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration…
- Codexis Announces Nestlé Health Science Exercises Option for Exclusive . . .
CDX-6114 is Codexis’ first internally developed biotherapeutic product candidate The exercise of the option triggers a $3 million milestone payment Upon exercising its option, Nestlé Health Science has now assumed all responsibility for future clinical development and commercialization of CDX-6114
- Codexis Names Ross Taylor Senior Vice President and Chief Financial . . .
REDWOOD CITY, Calif , Aug 06, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc (Nasdaq: CDXS), a leading protein engineering company, announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effective August 19, 2019
|